Other Events ·
On September 3, 2026, Milestone Pharmaceuticals Inc. announced that China’s National Medical Products Administration…
MISTMilestone Pharmaceuticals Inc.
On September 3, 2026, Milestone Pharmaceuticals Inc. announced that China’s National Medical Products Administration approved etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia in adults. This regulatory approval marks the first authorization of etripamil outside the United States and triggers a $2.0 million milestone payment to Milestone under its exclusive license agreement with Everest Medicines, which leads commercialization in Greater China. The company remains eligible for up to $98.0 million in additional milestones and tiered royalties of up to 18% on future sales. Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines.